 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Name:
|
Leuprolide
|
|
Other Names:
|
Leuprolide acetate
|
|
Therapy Types:
|
pharmacological
|
|
Development Status:
|
investigational in U.S.
|
|
FDA Phase:
|
Discontinued
|
|
Primary Medical Role:
|
Approved for treatment of prostate cancer in men;
endometriosis in women; early onset of puberty in
children; and uterine fibroids in women. Marketed under
brand name Lupron Depot® (leuroprolide acetate in
depot suspension) for treatment of prostate cancer,
endometriosis, fibroids, and central precocious puberty.
Also marketed under brand name Viadur® (leuprolide
acetate implant) for the treatment of advanced prostate
cancer.
|
|
Role in Alzheimer's Disease:
|
May improve cognitive function and slow the
progression of Alzheimer's disease. For more on underlying
rationale, see ARF
news story
|
|
Pharmacological Role:
|
Leuprolide is a luteinizing hormone-releasing hormone (LH-
RH) agonist and acts as a potent inhibitor of gonadotropin
secretion when given continuously and in therapeutic
doses. When given regularly to men and boys, leuprolide
decreases testosterone levels. When given regularly to
women and girls, leuprolide decreases estrogen levels.
|
|
Side Effects:
|
Side effects of this medication are not common, but may
include fast or irregular heartbeat; bone, muscle, or
joint pain; hot flashes; light, irregular vaginal bleeding
in females; and others. Marketed under brand name Lupron
Depot® (leuroprolide acetate in depot suspension) for
treatment of prostate cancer, endometriosis, fibroids, and
central precocious puberty. Also marketed under brand
name Viadur® (leuprolide acetate implant) for the
treatment of advanced prostate cancer.
|
|
Notes:
|
See Medline Plus Drug Information: Leuprolide [MedMaster]
and Leuprolide (Systemic) [USP DI]
.
|
Casadesus G, Zhu X, Atwood CS, Webber KM, Perry G, Bowen
RL, Smith MA. Beyond estrogen: targeting gonadotropin
hormones in the treatment of Alzheimer's disease. Curr
Drug Targets CNS Neurol Disord. 2004 Aug ;3(4):281-5. Abstract
Bowen RL, Verdile G, Liu T, Parlow AF, Perry G, Smith MA,
Martins RN, Atwood CS. Luteinizing hormone, a reproductive
regulator that modulates the processing of amyloid-beta
precursor protein and amyloid-beta deposition. J Biol
Chem. 2004 May 7;279(19):20539-45. Abstract
Bowen RL, Smith MA, Harris PL, Kubat Z, Martins RN,
Castellani RJ, Perry G, Atwood CS. Elevated luteinizing
hormone expression colocalizes with neurons vulnerable to
Alzheimer's disease pathology. J Neurosci Res. 2002 Nov
1;70(3):514-8.
Abstract
Short RA, Bowen RL, O'Brien PC, Graff-Radford NR. Elevated
gonadotropin levels in patients with Alzheimer disease.
Mayo Clin Proc. 2001 Sep;76(9):906-9.
Abstract
Bowen RL, Isley JP, Atkinson RL. An association of
elevated serum gonadotropin concentrations and Alzheimer
disease? J Neuroendocrinol. 2000 Apr;12(4):351-4.
Abstract
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Participate in Research
See a list of research studies, projects, and clinical trials in search of research participants.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
